National Health Investors (NHI)
(Delayed Data from NYSE)
$72.10 USD
-0.28 (-0.39%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $72.09 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
National Health Investors (NHI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$68.00 | $73.00 | $65.00 | -5.69% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for National Health Investors comes to $68.00. The forecasts range from a low of $65.00 to a high of $73.00. The average price target represents a decline of 5.69% from the last closing price of $72.10.
Analyst Price Targets (6 )
Broker Rating
National Health Investors currently has an average brokerage recommendation (ABR) of 1.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on eight recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy, representing 57.14% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NHI.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.86 | 1.86 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/30/2024 | Wells Fargo Securities | James Feldman | Strong Buy | Strong Buy |
4/4/2024 | Truist Securities | Michael Lewis | Hold | Hold |
3/15/2024 | KeyBanc Capital Markets | Austin Wurschmidt | Hold | Hold |
3/11/2024 | BMO Capital Markets | John P Kim | Hold | Strong Buy |
2/28/2024 | Not Identified | Not Identified | Hold | Hold |
2/26/2024 | Wedbush Securities | Richard Anderson | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.86 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 7 |
Average Target Price | $68.00 |
LT Growth Rate | NA |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | 1.10 |